文献速递淋巴瘤白血病

来那度胺维持治疗经治慢性淋巴细胞白血病(CONTINUUM):一项随机、双盲、安慰剂对照3期试验

Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2017-09-25

CONTINUUM试验在21国111家中心纳入314例经二线治疗的慢性淋巴细胞白血病患者,随机接受来那度胺2.5 mg/日或安慰剂维持。中位随访31.5个月,总生存无显著差异(HR 0.96),无进展生存来那度胺组显著延长(33.9 vs 9.2个月,HR 0.40)。来那度胺可能延迟后续治疗时间且不影响后续治疗反应。

要点

  • 来那度胺组中位无进展生存33.9个月,安慰剂组9.2个月(HR 0.40,P<0.0001)。
  • 总生存两组无显著差异(HR 0.96,95%CI 0.63-1.48,P=0.86)。
  • 3/4级中性粒细胞减少来那度胺组60% vs 安慰剂组23%。

核心结论

  • 来那度胺可能延迟至后续治疗的时间,且不影响对后续治疗的反应。
  • 化疗免疫治疗后予来那度胺维持,对于无法获得激酶抑制剂的患者可能是一种有效治疗选择。

研究设计与样本

  • 随机、双盲、安慰剂对照3期试验(CONTINUUM),在21个国家111家医院、医疗中心和诊所开展。
  • 纳入314例经两线治疗(二线治疗后至少达部分缓解)的慢性淋巴细胞白血病患者,随机1:1分配至来那度胺2.5 mg/日(n=160)或安慰剂(n=154),28天为一周期,直至疾病进展或不可接受毒性。
  • 来那度胺耐受良好时可剂量递增至5 mg或10 mg/日;随机化按年龄、二线治疗反应和预后因素分层。

主要发现

  • 中位随访31.5个月(IQR 18.9-50.8),总生存两组无显著差异:来那度胺组中位70.4个月(95%CI 57.5-不可估计)vs 安慰剂组不可估计(95%CI 62.8-不可估计),HR 0.96(95%CI 0.63-1.48),P=0.86。
  • 无进展生存来那度胺组显著长于安慰剂组:中位33.9个月(95%CI 25.5-52.5)vs 9.2个月(95%CI 7.4-13.6),HR 0.40(95%CI 0.29-0.55),P<0.0001。
  • 至第二次疾病进展或死亡时间(PFS2)来那度胺组显著长于安慰剂组:中位57.5个月(95%CI 47.7-不可估计)vs 32.7个月(95%CI 26.4-49.0),HR 0.46(95%CI 0.29-0.70),P<0.01。
  • 较基线反应改善:来那度胺组10/160例(6%)vs 安慰剂组4/154例(3%),P=0.12;至反应改善中位时间来那度胺组12.2周(IQR 7.2-22.5)vs 安慰剂组76.3周(IQR 20.2-182.6);反应改善持续时间两组均不可估计(来那度胺组95%CI 22.9-不可估计 vs 安慰剂组不可估计-不可估计)。
  • FACT-Leu和EQ-5D测量的健康相关生活质量在维持治疗期间两组无临床意义差异。

关键数值与推荐

  • 安全性人群中,最常见3/4级不良事件包括中性粒细胞减少(来那度胺组94/157例[60%] vs 安慰剂组35/154例[23%])、血小板减少(26例[17%] vs 10例[6%])和腹泻(13例[8%] vs 1例[<1%])。
  • 致死性不良事件共5例:来那度胺组3例(2%),安慰剂组2例(1%)。

临床怎么用

  • 作者认为,来那度胺可能延迟至后续治疗的时间,且不影响对后续治疗的反应。
  • 作者认为,化疗免疫治疗后予来那度胺维持,对于无法获得激酶抑制剂的患者可能是一种有效治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic leukaemia is unknown. Although kinase inhibitors can improve outcomes for some patients with relapsed and refractory disease, not all patients have access to these novel drugs. In this study, we aimed to assess the efficacy and safety of lenalidomide as maintenance therapy in patients with previously treated chronic lymphocytic leukaemia. METHODS: This randomised, double-blind, placebo-controlled, phase 3 trial (CONTINUUM) was done at 111 hospitals, medical centres, and clinics in 21 countries. Patients were eligible if they had chronic lymphocytic leukaemia; were aged 18 years or older; had been treated with two lines of therapy (with at least a partial response after second-line therapy); had received a purine analogue, bendamustine, anti-CD20 antibody, chlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative Oncology Group performance score of 0-2. Eligible patients were randomly assigned (1:1) by an interactive voice-response system to receive either oral lenalidomide (2·5 mg/day) or matching oral placebo capsules (2·5 mg/day) for 28-day cycles, until disease progression or unacceptable toxicity. Lenalidomide dose escalation (to 5 mg or 10 mg per day) was permitted if the drug was well tolerated. Patients, investigators, and those completing data analyses were masked to treatment allocation. Randomisation was stratified by age, response to second-line therapy, and prognostic factors. Co-primary endpoints were progression-free survival and overall survival; the primary endpoint was later changed to overall survival after the data cutoff for this analysis. Secondary endpoints were time from randomisation to second disease progression or death (PFS2),32 tumour response (improvement in response and duration of response), safety, and health-related quality of life (HRQoL). Efficacy analyses were done in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT00774345, and is closed to accrual, but follow-up is ongoing. FINDINGS: Between Feb 16, 2009 and Sept 29, 2015, 314 patients with chronic lymphocytic leukaemia were enrolled and randomly assigned to receive either lenalidomide (n=160) or placebo (n=154). With a median follow-up of 31·5 months (IQR 18·9-50·8), there was no significant difference in overall survival between the lenalidomide and the placebo groups (median 70·4 months, 95% CI 57·5-not estimable [NE] vs NE, 95% CI 62·8-NE; hazard ratio [HR] 0·96, 95% CI 0·63-1·48; p=0·86). Progression-free survival was significantly longer in the lenalidomide group (median 33·9 months, 95% CI 25·5-52·5) than in the placebo group (9·2 months, 7·4-13·6; HR 0·40, 95% CI 0·29-0·55; p<0·0001). PFS2 was significantly longer in the lenalidomide group than in the placebo group (median 57·5 months [47·7-NE] vs 32·7 months [26·4-49·0]; HR 0·46, 95% CI 0·29-0·70; p<0·01). Improved responses from baseline were observed in ten (6%) of 160 lenalidomide-treated patients versus four (3%) of 154 placebo-treated patients (p=0·12). Median time to improved response was 12·2 weeks (IQR 7·2-22·5) in the lenalidomide group versus 76·3 weeks (20·2-182·6) in the placebo group. Duration of improved response was not estimable in either group (95% CI 22·9-NE in the lenalidomide group vs NE-NE for placebo). There were no clinically meaningful differences in HRQoL between lenalidomide-treated patients and placebo-treated patients, as measured by FACT-Leu and EQ-5D, during maintenance treatment. In the safety population, the most common grade 3 or 4 adverse events included neutropenia (94 [60%] of 157 patients in the lenalidomide group vs 35 [23%] of 154 patients in the placebo group), thrombocytopenia (26 [17%] vs ten [6%]), and diarrhoea (13 [8%] vs one [<1%]). There were five fatal adverse events (three [2%] patients in the lenalidomide group and two [1%] patients in the placebo group). INTERPRETATION: Lenalidomide might delay time to subsequent therapy and does not adversely affect response to subsequent therapy. Chemoimmunotherapy followed by lenalidomide maintenance could be an effective treatment option for patients with chronic lymphocytic leukaemia who do not have access to kinase inhibitors. FUNDING: Celgene Corporation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Chanan-Khan AA, Zaritskey A, Egyed M, et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017. PMID: 28958469. doi:10.1016/S2352-3026(17)30168-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。